POINT/COUNTERPOINT: Is There a Role for HCT as Upfront Therapy for Myelofibrosis in the Era of JAK Inhibitors? “No”
POINT/COUNTERPOINT: Is There a Role for HCT as Upfront Therapy for Myelofibrosis in the Era of JAK Inhibitors? “No”
Track: BMT Tandem "Scientific" Meeting
Saturday, March 1, 2014, 10:30 AM-12:00 PM
Texas C (Gaylord Texan)
Disclosures:
S. Verstovsek,
Incyte Corporation, PI on Study: Research Funding
Astrazeneca, PI on Study: Research Funding
Lilly Oncology, PI on Study: Research Funding
Roche, PI on Study: Research Funding
Geron, PI on Study: Research Funding
NS Pharma, PI on Study: Research Funding
Bristol Myers Squibb, PI on Study: Research Funding
Novartis, PI on Study: Research Funding
Celgene, PI on Study: Research Funding
Infinity Pharmaceuticals, PI on Study: Research Funding
YM Biosciences, PI on Study: Research Funding
Gilead, PI on Study: Research Funding
Seattle Genetics, PI on Study: Research Funding
Promedior, PI on Study: Research Funding
Astrazeneca, PI on Study: Research Funding
Lilly Oncology, PI on Study: Research Funding
Roche, PI on Study: Research Funding
Geron, PI on Study: Research Funding
NS Pharma, PI on Study: Research Funding
Bristol Myers Squibb, PI on Study: Research Funding
Novartis, PI on Study: Research Funding
Celgene, PI on Study: Research Funding
Infinity Pharmaceuticals, PI on Study: Research Funding
YM Biosciences, PI on Study: Research Funding
Gilead, PI on Study: Research Funding
Seattle Genetics, PI on Study: Research Funding
Promedior, PI on Study: Research Funding
See more of: Myeloproliferative Neoplasms: Biological and Therapeutic Advances
See more of: BMT Tandem "Scientific" Meeting
See more of: BMT Tandem "Scientific" Meeting